MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Immix Biopharma, Inc.(NASDAQ: IMMX)*
Organization & Developments: Immix Biopharma
Parents
Immix Biopharma, Inc.(NASDAQ: IMMX)*
Children
*In-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 which reported a 85% overall response rate (ORR) and 71% complete response/stringent complete response (CR/sCR) in its Phase 1b portion of the Phase 1b/2 trial to treat relapsed/refractory multiple myeloma.
2023: Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status_ seekingalpha.com
Jumps
Finance & Acquisitions: Immix Biopharma
Key People: Immix Biopharma